Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03946683 | Cyberknife for Early Stage Breast Cancer | completed | N/A | 26 | NYU Langone HealthOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2021 | clinicaltrials |
| 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response |
| completed |
| — |
| 30 |
| Biyun Wang, MDOTHER |
| 1 |
| Feb 16, 2021 |
| clinicaltrials |
| NCT03102307 | Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD) | completed | — | 548 | Kliniken Essen-MitteOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01796041 | Intraoperative Imaging of Breast Cancer With Indocyanine Green(ICG) | completed | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT01004744 | Pre-Surgical Intervention for Targeted Therapies for Breast Cancer | completed | N/A | 10 | Columbia UniversityOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT02632071 | ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer | completed | Phase 1 | 17 | Columbia UniversityOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT03243331 | An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer | completed | Phase 1 | 18 | Kathy MillerOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02375958 | PCA062 in pCAD-positive Tumors. | completed | Phase 1 | 47 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03544125 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | completed | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03365895 | Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)(CIPN) | completed | N/A | 17 | University of ArizonaOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03618017 | The ConnectedCancerCare Pilot Study (CCC)(CCC) | completed | N/A | 66 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02576106 | Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy(CRYOSE01) | completed | N/A | 22 | Centre Leon BerardOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00309491 | Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | completed | Phase 3 | 2,021 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 19, 2020 | clinicaltrials |
| NCT00309569 | Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients | completed | Phase 3 | 429 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Oct 14, 2020 | clinicaltrials |
| NCT02192333 | Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors | completed | N/A | 390 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT00496808 | Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast | completed | N/A | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT01983501 | A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | completed | Phase 1 | 57 | Seagen Inc.INDUSTRY | 2 | Sep 21, 2020 | clinicaltrials |
| NCT03397914 | Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections | completed | Phase 4 | 70 | National Cancer Institute, EgyptOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02622074 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | completed | Phase 1 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 10, 2020 | clinicaltrials |
| NCT02485678 | A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer(AToM) | completed | N/A | 1,460 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01139957 | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer | completed | — | 1,916 | Gynecologic Oncology GroupNETWORK | 1 | Sep 2, 2020 | clinicaltrials |
| NCT03651921 | Testing of the Cancer Thriving and Surviving Breast Cancer Program(COSS) | completed | N/A | 39 | Manuela EicherOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02159157 | A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer | completed | N/A | 28 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT01162200 | Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer | completed | Phase 1 | 75 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT02355262 | CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers | completed | — | 45 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT00005970 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | completed | Phase 3 | 3,436 | National Cancer Institute (NCI)NIH | 4 | Aug 14, 2020 | clinicaltrials |
| NCT01583426 | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)(GeparSepto) | completed | Phase 3 | 1,229 | GBG Forschungs GmbHOTHER | 1 | Aug 6, 2020 | clinicaltrials |
| NCT03140553 | TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer(neoCARH) | completed | Phase 2 | 140 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 28, 2020 | clinicaltrials |
| NCT01908101 | Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer | completed | Phase 2 | 86 | University of WashingtonOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT02362958 | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | completed | Phase 2 | 159 | Sun Yat-sen UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT02481128 | Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer | completed | N/A | 1,198 | Kliniken Essen-MitteOTHER | 2 | Jul 9, 2020 | clinicaltrials |
| NCT02247037 | Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer | completed | — | 68 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02348320 | Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy | completed | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02038010 | BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx | completed | Phase 1 | 17 | Northwestern UniversityOTHER | 1 | Jun 29, 2020 | clinicaltrials |
| NCT02441946 | A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer(neoMONARCH) | completed | Phase 2 | 224 | Eli Lilly and CompanyINDUSTRY | 10 | Jun 17, 2020 | clinicaltrials |
| NCT02816112 | Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia(REaCT-TC2) | completed | Phase 4 | 458 | Ottawa Hospital Research InstituteOTHER | 1 | May 27, 2020 | clinicaltrials |
| NCT01216111 | Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) | completed | Phase 3 | 647 | Fudan UniversityOTHER | 0 | May 19, 2020 | clinicaltrials |
| NCT02005770 | Anesthesia and Circulating Tumor Cells in Breast Cancer | completed | Phase 4 | 221 | University of ZurichOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT02061332 | DC Vaccine for Patients With Ductal Carcinoma In Situ(DCIS6) | completed | Phase 1 / Phase 2 | 58 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01855828 | Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer | completed | Phase 2 | 50 | Yale UniversityOTHER | 1 | Mar 31, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2021source: clinicaltrials